Syndax Pharmaceuticals, Inc. today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022, at 3:30 p.m.
| WALTHAM, Mass., Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022, at 3:30 p.m. ET. A live webcast of the fireside chat can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the event will also be available for a limited time. About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. Syndax Contacts Sharon Klahre SNDX-G
SOURCE Syndax Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:SNDX |
View original content:
